Ipsen S.A. (OTCMKTS:IPSEY – Get Rating)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $27.98 and traded as high as $29.94. Ipsen shares last traded at $29.94, with a volume of 1,794 shares traded.
Wall Street Analyst Weigh In
Separately, Morgan Stanley raised shares of Ipsen from an “underweight” rating to an “equal weight” rating in a research report on Thursday, February 16th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $107.22.
Ipsen Trading Down 0.8 %
The stock’s 50-day moving average price is $29.22 and its 200 day moving average price is $27.98.
Ipsen Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.